Corrections: A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study (The Lancet Infectious Diseases (2017) 17(11) (1190–1199) (S1473309917304474) (10.1016/S1473-3099(17)30447-4));A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study

The Lancet Infectious Diseases

Volumn 17, Issue 11, 2017, Pages 1190-1199

  Saunders, Matthew J ^a,b,c   Wingfield, Tom ^a,b,c,d,e   Tovar, Marco A ^b,c   Baldwin, Matthew R ^b,c,f   Datta, Sumona ^a,b,c   Zevallos, Karine ^b,c   Montoya, Rosario ^c   Valencia, Teresa R ^b   Friedland, Jon S ^a   Moulton, Larry H ^g   Gilman, Robert H ^g   Evans, Carlton A ^a,b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; COHORT ANALYSIS; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOUSEHOLD; HUMAN; INCIDENCE; INDOOR AIR POLLUTION; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NUMBERS NEEDED TO TREAT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SOCIOECONOMICS; TREND STUDY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VALIDATION STUDY; DISEASE TRANSMISSION; EPIDEMIOLOGY; MIDDLE AGED; PERU; RURAL POPULATION; TRANSMISSION; URBAN POPULATION; YOUNG ADULT;

ADULT; COHORT STUDIES; DISEASE TRANSMISSION, INFECTIOUS; EPIDEMIOLOGIC METHODS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERU; PROSPECTIVE STUDIES; RISK ASSESSMENT; RURAL POPULATION; TUBERCULOSIS; URBAN POPULATION; YOUNG ADULT;

EID: 85027718009     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30573-X     Document Type: Erratum

References (31)

1. Fox, GJ, Barry, SE, Britton, WJ, Marks, GB, Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 41 (2013), 140–156.
2. WHO. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries, 2012, World Health Organization, Geneva.
3. Alsdurf, H, Hill, PC, Matteelli, A, Getahun, H, Menzies, D, The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 16 (2016), 1269–1278.
4. Rangaka, MX, Cavalcante, SC, Marais, BJ, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 386 (2015), 2344–2353.
5. Tebruegge, M, Bogyi, M, Soriano-Arandes, A, Kampmann, B, Shortage of purified protein derivative for tuberculosis testing. Lancet, 384, 2014, 2026.
6. Uplekar, M, Weil, D, Lonnroth, K, et al. WHO's new End TB Strategy. Lancet 385 (2015), 1799–1801.
7. Saunders, MJ, Datta, S, Contact investigation: a priority for tuberculosis control programs. Am J Respir Crit Care Med 194 (2016), 1049–1050.
8. Hippisley-Cox, J, Coupland, C, Vinogradova, Y, Robson, J, May, M, Brindle, P, Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ, 335, 2007, 136.
9. WHO. Guidelines on the management of latent tuberculosis infection, 2015, World Health Organization, Geneva.
10. Smieja, M, Marchetti, C, Cook, D, Smaill, F, Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev, 1, 1999 CD001363.
11. Sterling, T, Villarine, ME, Borisov, A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365 (2011), 683–693.
12. Instituto Nacional de Estadística e Informática. Crecimiento Económico, Población, Características Sociales y Seguridad Ciudadana en la Provincia Constitucional del Callao, 2016, Instituto Nacional de Estadística e Informática, Lima.
13. Comstock, G, Baum, C, Snider, DJ, Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 119 (1979), 827–830.
14. Golub, JE, Cohn, S, Saraceni, V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 60 (2015), 639–645.
15. Chan, PC, Peng, SSF, Chiou, MY, et al. Risk for tuberculosis in child contacts: development and validation of a predictive score. Am J Respir Crit Care Med 189 (2014), 203–213.
16. Mandalakas, AM, Kirchner, HL, Lombard, C, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis 16 (2012), 1033–1039.
17. Zak, DE, Penn-Nicholson, A, Scriba, TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
18. Rangaka, MX, Wilkinson, KA, Glynn, JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 45–55.
19. Pelly, TF, Santillan, CF, Gilman, RH, et al. Tuberculosis skin testing, anergy and protein malnutrition in Peru. Int J Tuberc Lung Dis 9 (2005), 977–984.
20. Shanaube, K, Hargreaves, J, Fielding, K, et al. Risk factors associated with positive quantiFERON-TB gold in-tube and tuberculin skin tests results in Zambia and South Africa. PLoS One, 6, 2011, e18206.
21. Lönnroth, K, Williams, BG, Cegielski, P, Dye, C, A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol 39 (2010), 149–155.
22. WHO. Tuberculosis in the Americas: regional report, 2014, World Health Organization, Geneva.
23. Wingfield, T, Boccia, D, Tovar, M, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med, 11, 2014, e1001675.
24. Lin, HH, Ezzati, M, Murray, M, Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med, 4, 2007, e20.
25. Escombe, AR, Oeser, CC, Gilman, RH, et al. Natural ventilation for the prevention of airborne contagion. PLoS Med, 4, 2007, e68.
26. Datta, S, Sherman, JM, Bravard, MA, Valencia, T, Gilman, RH, Evans, CA, Clinical evaluation of tuberculosis viability microscopy for assessing treatment response. Clin Infect Dis 60 (2015), 1186–1195.
27. Jones-Lopez, EC, Namugga, O, Mumbowa, F, et al. Cough aerosols of Mycobacterium tuberculosis predict new infection a household contact study. Am J Respir Crit Care Med 187 (2013), 1007–1015.
28. Grandjean, L, Gilman, RH, Martin, L, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. PLoS Med, 12, 2015, e1001843.
29. Morán-Mendoza, O, Marion, SA, Elwood, K, Patrick, D, FitzGerald, JM, Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 14 (2010), 1112–1119.
30. Saunders, MJ, Koh, GCKW, Small, A, Dedicoat, M, Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study. Int J Tuberc Lung Dis 18 (2014), 640–646.
31. Pun, M, Situacion de la Epidemia de VIH en el Peru. https://www.minsa.gob.pe/portada/Especiales/2015/vih/matcom/Situacion-Epidemiologica-VIH-2015.pdf, Nov 28, 2015 (accessed Dec 21, 2016).